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Background: Glycogenosis type II or Pompe disease is an autosomal-recessive lysosomal storage disease due to
mutations in the gene encoding acid alpha-glucosidase (GAA), an enzyme required for lysosomal glycogen
degradation. The disease predominantly affects the skeletal and respiratory muscles but there is growing evidence
of the involvement of smooth muscle cells in blood vessel walls, suggesting a multi-system disorder. Moreover, the
failure of autophagy in Pompe disease could contribute to muscular atrophy and disease progression and is
thought to compromise the efficacy of enzyme replacement therapy (ERT).
Methods: We investigated the light microscopical and ultrastructural pathology of the arrector pili muscle from
punch skin biopsies from the calf of 6 adult Pompe disease patients and 6 age and gender matched healthy
controls. Two patients had a follow-up biopsy after 19 and 20 month of ERT.
Results: The electron microscopic investigation of patient biopsies revealed the widespread occurrence of
glycogenosomes, membrane bound accumulations of granular glycogen, associated with autophagic vacuoles. In
the controls we detected only muscle cells with non-membrane bound forms of glycogen. These morphological
changes in smooth muscle cells are similar to those seen in skeletal muscle and smooth muscle cells of arterioles of
Pompe patients. Furthermore, two patients with pre- and post-ERT skin biopsies showed a decrease in the number
of cells with extensive autophagy after treatment.
Conclusions: Electron microscopic examination of the arrector pili muscles appears to be a surrogate marker for
the involvement of smooth muscles reflecting disease severity. These findings suggest that the standardized and
widely used skin biopsy could offer a minimally invasive way to screen for smooth muscle involvement and warrant
further studies in larger cohorts of patients.
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Glycogenosis type II or Pompe disease (MIM #232300),
is an autosomal recessive lysosomal storage disease due
to mutations in the gene encoding acid α-glucosidase
(GAA), an enzyme required for glycogen degradation in
lysosomes. Phenotypes range from a severe neonatal onset
form with cardiac involvement to a milder adult onset
form, which is characterized by skeletal and respiratory
muscle weakness [1-3]. Intravenous enzyme replacement
therapy (ERT) with recombinant α-glucosidase has been
available and is approved for children and adults since
2007 [4,5].* Correspondence: ikatona@ukaachen.de
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stated.The use of skeletal muscle biopsies as an early diag-
nostic tool is an invasive procedure and can lead to false
negative results [1-3,6]. A blood-based GAA enzyme ac-
tivity assay is currently recommended to screen for GAA
deficiency and is able to confirm or exclude Pompe dis-
ease in all age groups. The diagnosis should be confirmed
either by a second GAA enzyme activity assay or GAA se-
quencing [1-3,6].
There is growing evidence for an involvement of smooth
muscle fibers indicating a multi-system disorder [5,7-10].
Pathological glycogen accumulation has been found in
smooth muscles cells of arteries, veins, and bronchioles
[5,7,11]. ERT has led to the reduction of glycogen aggre-
gates in the smooth muscle cells of arteries and veins in aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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with infantile Pompe disease [5,7].
Skin punch biopsy is an established and standardized
procedure to analyse the arrector pili muscle, composed
of smooth muscle cells [12-14]. In the present study we
analysed the arrector pili muscle in skin punch biopsies
from adult patients with Pompe disease prior to and dur-
ing ERT and compared the glycogen accumulation with
normal controls.
Methods
Patients, controls, biopsy material
We examined 6 adult patients (2 males, 4 females; mean
age 48,5 years) with biochemically and genetically con-
firmed Pompe disease. At the time point of biopsy 2 of
the patients had been receiving ERT and 4 had not yet
started ERT. In 2 of the latter patients, a second biopsy
was performed after commencing ERT. All patients gave
their informed consent. The study was approved by the
local ethics committee of Martin-Luther-University Halle
(Saale). Skin biopsies from 6 healthy individuals obtained
from the diagnostic skin biopsy archive of the Institute of
Neuropathology, RWTH Aachen University, were used as
controls.
A 3 mm skin punch biopsy was taken from the stand-
ard location of 10 cm proximally of the lateral malleus [14]
to screen for glycogen deposits and vacuoles in smooth
muscle cells of the arrector pili muscles by light and elec-
tron microscopy. Archived diagnostic skeletal muscle biop-
sies obtained from six adult patients (2 male; 4 female;
mean age 43.7 years) with genetically confirmed, untreated
Pompe disease were also analysed by light and electron mi-
croscopy. These were used to compare the ultrastructural
morphological changes in skeletal and arrector pili muscle
with special focus on glycogen accumulation and vacuoli-
sation within skeletal muscle fibers, endothelial cells and
smooth muscle cells of the small intramuscular blood ves-
sels. Skeletal muscle biopsies prior to ERT were not avail-
able for any of the patients undergoing skin punch biopsy.
Immunohistochemistry, light and electron microscopy
Cryostat sections of formalin fixed, Tissue-Tek O.C.T.
compound (Sakura Finetek Europe, Zoeter Woude,
The Netherlands) embedded tissues were stained with
hematoxylin and eosin (H&E), periodic acid Schiff stain
(PAS) and with anti-p62 (Abcam, mouse monoclonal anti-
body, visualized with HRP conjugated secondary anti-
mouse antibody, Cell Signalling Technology). For electron
microscopy, glutaraldehyde-fixed tissue specimens were
post-fixed with 1% OsO4 in 0.1 M cacodylate buffer con-
taining 50 mM K3Fe (CN)6 and embedded in epoxy resin.
Ultramicrotome cut semithin sections from the resin
blocks were stained with toluidine blue and paraphenylene
diamine. Ultrathin sections were contrast enhancedwith uranyl acetate and lead citrate and examined with a
Philips EM 400 T electron microscope and images were
captured using a Morada digital camera as previously de-
scribed [15].
Quantification of glycogen deposition in smooth muscle
cells
The glycogen content of arrector pili smooth muscle
cells was assessed semiquantitatively using electron mi-
crographs of randomly selected fields on the cross sec-
tions of the muscles. The individual smooth muscle cells
were then manually examined, counted and assigned to
five categories according to their glycogen content (see
legend of Figure 1). We counted 849 cells from controls
and 1511 cells from Pompe disease patients. The chi-
squared test was used to compare the patient and con-




Clinical characteristics of the adult Pompe patients
are given in Table 1. The mean age at examination was
48.5 years. All patients had proximal paresis of arms and
legs. No patient was wheelchair-bound or depended on
nocturnal non-invasive ventilation. For the two patients
(P4 and P5) who had received ERT after the first skin bi-
opsy, the second skin biopsies were obtained 19 and 20
months after ERT, respectively.
Skeletal muscle histology
In PAS and H&E stained paraffin and cryostat sections,
in semithin sections stained with toluidine blue and by
electron microscopy we observed vast intermyofibrillar
and subsarcolemmal glycogen accumulations (Figure 2A)
associated with autophagic vacuoles in all Pompe patient-
derived muscle biopsies (Figure 2B). Increased and abnor-
mal glycogen accumulations were also found in fibroblasts
in the vicinity of endomysial capillaries, in smooth muscle
cells of intramuscular arterioles and in small arteries
(Figure 2C).
Skin biopsy
Light microscopy of PAS stains did not reveal any differ-
ences in arrector pili smooth muscles from controls and
Pompe patients (Figure 3A-B), which could result from
the inadequacy of our tissue preparation for the proper
visualization of glycogen accumulation. The toluidine
blue staining of the semithin sections showed the mem-
brane bound nature of the glycogen deposits and accu-
mulations of autophagic vacuoles in Pompe disease
cases (Figure 3C-D). The autophagic origin of these vac-
uoles was confirmed by p62 staining (Figure 3E-F). The
role of p62 is to link the ubiquitinated cargos to the
Figure 1 Quantification of cytoplasmic glycogen content in smooth muscle cells of arrector pili muscle. The smooth muscle cells were
assigned to five categories: 1 - No visible glycogen content; 2 – Scattered glycogen granules; 3 - Large amount of granular glycogen;
4 – Glycogenosomes; 5 – Extensive autophagy, filling a significant part of the cytoplasm. A: A large fraction of smooth muscle cells from Pompe
patients shows abnormal forms of glycogen accumulation, while the cells in controls contain mainly no or granular glycogen, which is
considered as a normal property for this cell type. (Chi square test: p < 0,0001); B: The number of cells containing glycogenosomes or
presenting extensive autophagy is decreased after ERT in the two patients where a follow up biopsy was available. (Significance could
not be determined due to the low subject number).
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widely used as a marker for accumulation of autophagic
vacuoles [16]. However, unequivocal differences could
only be demonstrated by electron microscopic examin-
ation. Arrector pili smooth muscle cells from Pompe dis-
ease patients showed vastly increased glycogen storage in
glycogenosomes associated with prominent, pleomorphic,
mostly granular accumulations in autophagic vacuolesTable 1 Clinical characteristics and laboratory findings of 6 a
P1 P2a
Sex Female Female
Age (year) 22 53
Durations of symptoms in years 12 27
Duration of ERT in months 24 0
GAA genotype c.-45 T > G*;
IVS9-1G > C
c.-45 T > G;
IVS16 + 102_IVS17 +
6 minute walk test (m) 510 130
Walking aids No Yes
Walton Gardner Medwin Scalec 3 6
Slow Vital capacity (%) 60 56
α-glucosidase activity
At pH 3.8 0.59 0.36
With inhibition (dry blood spot test**) 0.14 0.17
aSiblings.
bSiblings.
cThe Walton-Gardner-Medwin Scale (WGMS) is a 10-item scale to asses the degree
In brackets is the duration of ERT in months at the time of the second biopsy.
ERT enzyme replacement therapy, GAA acid α-glucosidase,
*c.-45 T > G stands for c.-32-13 T > G.
**Normal range of α-glucosidase acitivity at pH 3.8: 1.5 – 10.0 nmol/spot*21 hours;(Figure 2F-I). In contrast, control smooth muscle cells also
showed glycogen accumulations but these were less
pronounced, not as densely packed and not membrane-
bound. Such granular glycogen deposits were in many
cases loosely associated with sub-cellular structures, such
as mitochondria or plasma membrane and endoplasmic
reticulum, but were not associated with prominent au-
tophagic vacuoles (Figure 2D-E).dult Pompe patients
P3a P4b P5b P6
Female Male Female Male
50 47 56 63
24 10 16 11
0 0 (19) 0 (20) 12
31
c.-45 T > G;
IVS16 + 102_IVS17 + 31
c.307 T > G;
c.1478C > T
c.307 T > G;
c.1478C > T
c.-45 T > G:
c.925G > A
430 450 420 120
No No No Yes
2 4 3 6
96 91 73 44
1.06 1.17 0.72 1.58
0.39 0.32 0.05 0.18
of walking disability (0 normal walking, 7 wheelchair bound).
with inhibition: 0.9-7.2 nmol/spot*21 hours.
Figure 2 Electron microscopy of skeletal muscle and arrector pili smooth muscle of Pompe disease patients and controls. A: Granular
glycogen accumulation disrupting the myofibrilar structure in skeletal muscle of a Pompe patient. Scale bar: 0,5 μm. B: Intramyofibrilar
glycogenosome accumulation with varying density of the glycogen deposits, associated with autophagic vacuoles in the skeletal muscle of a
Pompe disease patient. Scale bar: 1 μm. C: Large glycogenosomes containing tightly packed glycogen granules (arrows) in a smooth muscle cell
of an intramuscular blood vessel from a patients muscle biopsy. Scale bar: 2 μm. D-E: Smooth muscle cells of arrector pili muscle from a skin
biopsy of a healthy control. Many cells contain granular, non-membrane bound glycogen deposits (arrows) which are frequently associated
loosely with the cellular membrane or mitochondria (arrowheads). Scale bar D: 2 μm; E: 1 μm. F-G: Glycogen appears in membrane bound
(arrows) and also in granular form (arrowhead) in the arrector pili smooth muscle cells of Pompe patients. Scale bar F: 0,5 μm; G: 5 μm. H: Smooth
muscle cells from arrector pili muscle of Pompe patients contain similar vacuoles that we can observe in skeletal muscle of such patients,
containing diverse forms of glycogen and autophagic material. Scale bar: 1 μm. I: The glycogenosomes and autophagic vacuoles fill the entire
cytoplasm of the arrector pili smooth muscle cells in some cases, severely disrupting their structure. Scale bar: 2 μm.
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Quantitative analysis confirmed that although many
smooth muscle cells (78%) in controls contained glycogen,the typical form of glycogen was as small granular de-
posits. Only 7% of cells showed an elevated number of de-
posits and less than 1% contained membrane-bound
Figure 3 PAS staining, p62 immunohystochemistry and Toluidine blue staining of arrector pili muscles from control and Pompe patients
skin biopsies. A-B: The different types of glycogen accumulation (granular glycogen versus membrane bound form) are indistinguishable with PAS
staining of controls (A) and patients (B). C-D: Toluidine blue staining of semithin sections shows granular glycogen accumulations in control (arrows, C)
and glycogenosomes (arrows, D) in Pompe patient biopsies. E-F: Immunohistochemistry against p62 (a marker for autophagy) shows accumulations in
patient arrector pili muscle (F, arrows) but not in healthy controls (E). Scale bar for all parts: 20 μm.
Table 2 Distribution of glycogen content in arrector pili
smooth muscle cells in patients prior to and during ERT
1 2 3 4 5
P4 before ERT 15, 6 31, 8 2, 6 41, 1 8, 9
P4 after ERT 21, 0 42, 0 1, 4 29, 7 5, 8
P5 before ERT 9, 1 55, 3 1, 5 25, 0 9, 1
P5 after ERT 16, 7 44, 0 4, 2 29, 6 5, 6
Categories are as described in the legends of Figure 1. The numbers in the
table represent percentages of the total counted cell numbers.
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control cells. In contrast, 37% of Pompe disease patient-
derived arrector pili smooth muscle cells contained abnor-
mal forms of glycogen; among these 11% showed accumu-
lation of autophagic vacuoles filling a significant part of
the cytoplasm. The distribution of these different forms of
glycogen deposits was significantly different between pa-
tients and controls (p > 0,0001) (Figure 1A).
We also compared the pre- and post-ERT biopsies in
two cases. In the pooled quantification data of these two
cases we saw a decrease in the number of cells contain-
ing glycogenosomes (33.1% vs. 29.7%) and also in those
severely affected by autophagy (from 9.0% to 5.7%). The
distribution for the two treated patient can be seen in
Table 2. Due to the small number of subjects (n = 2) and
the high individual variation in patients, a comprehen-
sive statistical analysis of the patterns of intracellular
glycogen deposition before and after ERT was not
possible, even though the decrease in cells affected by
autophagy compared to all other cells was significant
(p = 0.003) (Figure 1B).
Discussion
In the present study we describe the prominent glycogen
accumulation in the arrector pili smooth muscle fibersas an easily accessible representative of smooth muscle
in adult patients with Pompe disease. The electron
microscopic finding of glycogenosomes associated with
autophagic vacuoles distinguished adult Pompe disease
patients from controls. Glycogenosomes, i.e. glycogen-
filled lysosomes are the hallmark of Pompe disease
[1-3,5,7]. Light microscopy of PAS stained sections of
formalin fixed material was, by itself, not sufficient to
differentiate samples from Pompe disease patients and
controls. The analysis of follow-up samples from pa-
tient undergoing ERT suggested a mild beneficial thera-
peutic effect, as indicated by a slight reduction in the
number of glycogenosomes and autophagic vacuoles in
the arrector pili muscles. This effect needs to be verified
in a larger group of patients.
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ation between autophagy and skeletal muscle atrophy,
and disease progression. In a single adult case, ERT re-
sulted in a decrease of autophagic aggregates and skel-
etal muscle fibre vacuolisation [17]. A similar trend was
seen in our de novo treated patients. The presence of ex-
cessive autophagy in smooth muscle associated with ab-
normal glycogen accumulation is particularly interesting
since autophagy is thought to have a direct role in
the pathomechanism of Pompe disease [18,19] and its
negative effect to ERT efficiency has been demon-
strated in animal models [20]. Because the morpho-
logical alterations of skeletal and smooth muscle are
remarkably similar, the arrector pili muscle appears to
be suitable for the study of these pathomechanisms in
human patients.
In conclusion, our findings suggest that the standardized
skin biopsy technique could offer an easy and minimally
invasive way to screen for smooth muscle involvement in
Pompe disease and warrant further studies in larger co-
horts of patients. Furthermore, arrector pili muscle path-
ology might even be useful as a surrogate marker for the
involvement of smooth muscles in other tissues, reflecting
disease severity.
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